All News

Efficacy and Safety of Xeligekimab in AS Dr. Adela Castro reports on abstract OP0102 at the EULAR 2025 meeting in Barcelona, Spain https://t.co/xpzeV0oZOr https://t.co/mEYnAFsYQI

Efficacy and Safety of Xeligekimab in AS | RheumNow

RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its faculty.

Intraarticular IL-1Ra Gene Therapy in Knee Osteoarthritis In a dose-escalation trial in nine participants, they observed that a single intra-articular injection of the gene product led to an increase in IL-1Ra in the synovial fluid that remained elevated for up to a year. There https://t.co/YDuUg44ebu

Transcranial Stimulation is Effective in Fibromyalgia A randomized, controlled clinical trial in fibromyalgia (FM) has shown the efficacy of transcranial direct current stimulation (A-tDCS) (along with exercise and pain neuroscience education [PNE]), in alleviating the pain. https://t.co/kJk1R8ubqk

RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its Faculty

Secukinumab Use in Refractory Giant Cell Arteritis In 2023, the phase 2 TitAIN study showed that the effectiveness and safety of secukinumab in 52 patients with giant cell arteritis (GCA) who had an inadequate response to tocilizumab. While we await the results of a larger https://t.co/HkMT9QEMg8

2025 EULAR/ACR Risk Stratification Criteria for At-Risk Arthralgia A collaborative EULAR/ACR expert panel has established criteria for arthralgia patients at risk (clinically suspect arthralgia) to progress to chronic rheumatoid arthritis (RA). Risk stratification of CSA https://t.co/STmuNO3c2Z

⌛️ Diagnostic delay in #SpA: Better with time? 🔹️Data from the @Official_ASAS Study 🔹️4339 patients 🔹️Delay decreased over time 🔹️Same trends across world regions & across Human Development Index categories POS0908 #EULAR2025 @RheumNow https://t.co/Y9gxQDV9KJ

https://x.com/Nellziade/status/1933285961519292729/photo/1

EULAR Points to consider for the definition of D2M and TR #Psoriatic_Arthritis Presented by Dr Helena Marzo-Ortega at #EULAR2025 @RheumNow https://t.co/3LsJvSiXJV

https://x.com/Nellziade/status/1933800344007684474/photo/1

Sometimes you hear: “PMR dose steroids don’t really matter” Errrrr… (You wouldn’t accept this steroid exposure in any other disease. Never) #EULAR2025 POS0139 @RheumNow https://t.co/o6w2RpaGBj

https://x.com/drdavidliew/status/1933077212607246599/photo/1

In the United States, IL-6R inhibitors have continued to help PMR patients get off steroids. Hopefully more use and more options mean that, in the future, PMR patients get no more steroids than PsA or RA patients #EULAR2025 POS0948 @RheumNow https://t.co/JT7gFDC5rl

https://x.com/drdavidliew/status/1933513969245041109/photo/1

The new (provisional) 2025 EULAR/ACR classification criteria for anti-synthetase syndrome #EULAR2025 @RheumNow https://t.co/X6VjcN8XZe

@RheumNow EULAR haemochromatosis arthropathy classification criteria Patrick Kiely: please photograph this and take it back to your communities Patient association lead comes to the microphone, and thanks them for making be seen. 🥲 #EULAR2025 @RheumNow https://t.co/9bqdV0fuPk

https://x.com/drdavidliew/status/1933797947738558480/photo/1

Management of SLE: -Treat early to prevent organ damage -Taper GC to <5mg/d in the first 6m when feasible -New therapies are promising but still unmet needs in LN, limited global access and lacking data in pregnancy. #EULAR2025 @RheumNow https://t.co/UKK8sTYJD2

-Difficult to treat RA is a heterogeneous concept -Risk fx: younger onset, high disease activity,erosive disease, comorbidities, depression. -Study in a Spanish cohort with D2T 2/2 inefficacy showed Rituximab, JAKis, and IL-6i had longer survival (hence better tx options). -The https://t.co/ZCZcX9FRfb

https://x.com/AdelaCastro222/status/1932392453698388399/photo/1

Impact of TNFi on efficacy of Vunakizumab in AS. -Post hoc analysis of Vunakizumab (humanized monoclonal IgG1/k antibody targeting IL-17A) trial on AS pts. -440 total pts, 163 had prior TNFi exposure - At week 16, no significant differences in ASAS20 b/w TNFi exposed pts https://t.co/O9PFOuLa5l

https://x.com/AdelaCastro222/status/1933460354933141729/photo/1

#EULAR2025 Abstr#OP0041 FcRn-inhibition is showing consistency in #Sjogren. Last year it was Nipocalimab. This proof-of-concept study showed efgartigimod met its primary endpoint, the CRESS response. No difference in ESSPRI. Phase 3 UNITY is underway @RheumNow https://t.co/jw1i4FqkIh

https://x.com/Yuz6Yusof/status/1932933881730072742/photo/1

#EULAR2025 Abstr#OP0035 SGLT2-i and GLP-1 agonist are increasingly used to treat diabetes. Population based study in Canada showed no significant difference in risk of developing an autoimmune rheumatic disease with GLP-1-RA or SGLT2i relative to DPP4i treatment @RheumNow https://t.co/CvPcOqehtl

https://x.com/Yuz6Yusof/status/1932939395834818772/photo/1

#EULAR2025 Abstr#OP0202 Phase 1/2 of Resel-cel, a 4-1BB-containing human CD19-CAR T cell (weight-based 1 x infusion) reported efficacy in 8 patients (#SLE and LN) at WK28. 2 x Grade 1 CRS & 1 x Grade 4 ICANS. 1 x HLH, not attributed to SLE flare. Need longterm data @RheumNow https://t.co/COCKlqw687

https://x.com/Yuz6Yusof/status/1933397540470182033/photo/1

#EULAR2025 Abstr#OP0265 Do we have convenient biomarkers to help predict new ANA+ referral who would progress to #SLE #Sjogren at 12 mths? Proteomics analysis identified IFN and B-cell markers. Validation is needed and to incorporate clinical items into prognostic model @RheumNow https://t.co/TWClLTKQ0b

https://x.com/Yuz6Yusof/status/1933460933751238740/photo/1

Topics

All News

Do you get our email newsletter?